These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24382638)

  • 1. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
    Younossi Z; Negro F; Serfaty L; Pol S; Diago M; Zeuzem S; Andreone P; Lawitz EJ; Roberts S; Focaccia R; Foster GR; Horban A; Lonjon-Domanec I; Coate B; DeMasi R; Picchio G; Witek J
    Hepatology; 2013 Dec; 58(6):1897-906. PubMed ID: 24382638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
    Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
    Grasso A; Malfatti F; De Leo P; Martines H; Fabris P; Toscanini F; Anselmo M; Menardo G
    J Hepatol; 2009 Dec; 51(6):984-90. PubMed ID: 19695729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
    Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
    De Meyer S; Dierynck I; Ghys A; Beumont M; Daems B; Van Baelen B; Sullivan JC; Bartels DJ; Kieffer TL; Zeuzem S; Picchio G
    Hepatology; 2012 Dec; 56(6):2106-15. PubMed ID: 22806681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
    Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
    Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
    Bortoletto G; Scribano L; Realdon S; Marcolongo M; Mirandola S; Franceschini L; Bonisegna S; Noventa F; Plebani M; Martines D; Alberti A
    J Viral Hepat; 2010 Jul; 17(7):475-80. PubMed ID: 19878535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Int J Infect Dis; 2012 Jun; 16(6):e436-41. PubMed ID: 22486858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
    Romero-Gómez M; Diago M; Andrade RJ; Calleja JL; Salmerón J; Fernández-Rodríguez CM; Solà R; García-Samaniego J; Herrerías JM; De la Mata M; Moreno-Otero R; Nuñez O; Olveira A; Durán S; Planas R;
    Hepatology; 2009 Dec; 50(6):1702-8. PubMed ID: 19845037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
    Aghemo A; Prati GM; Rumi MG; Soffredini R; D'Ambrosio R; Orsi E; De Nicola S; Degasperi E; Grancini V; Colombo M
    Hepatology; 2012 Nov; 56(5):1681-7. PubMed ID: 22619107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
    Huang JF; Dai CY; Yu ML; Huang CF; Huang CI; Yeh ML; Yang JF; Hou NJ; Hsiao PJ; Lin ZY; Chen SC; Shin SJ; Chuang WL
    Liver Int; 2011 Sep; 31(8):1155-62. PubMed ID: 21745292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
    Conjeevaram HS; Wahed AS; Afdhal N; Howell CD; Everhart JE; Hoofnagle JH;
    Gastroenterology; 2011 Feb; 140(2):469-77. PubMed ID: 21070775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
    J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
    Hsu CS; Hsu SJ; Lin HH; Tseng TC; Wang CC; Chen DS; Kao JH
    J Formos Med Assoc; 2014 Oct; 113(10):716-21. PubMed ID: 24974131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.